FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today!

About | Sample | Privacy
Related Topics >> Eli Lilly | Cymbalta

Lilly trumpets Cymbalta as arthritis med

Tools

Eli Lilly's Cymbalta might make the leap from psychiatric med to arthritis treatment. The company announced today that a study showed that 59 percent of patients saw their pain cut by 30 percent with Cymbalta, and 47 percent had a 50 percent reduction. That's compared with 45 percent and 29 percent on placebo, respectively. It wouldn't be Cymbalta's first painkilling indication; it's also approved for diabetic nerve pain. Report

More stories about Eli Lilly   Cymbalta  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 4 + 2?
To combat spam, please solve the math question above.